REFERENCES
1. Administration USFaD. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Avaliable from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools [Last accessed on 16 Jan 2024].
2. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
3. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-9.
4. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
5. Boone B, Jacobs K, Ferdinande L, et al. EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol 2011;38:492-502.
6. Administration USFaD. Transcript biomarker terminology - speaking the same language. Avaliable from: https://www.fda.gov/drugs/biomarker-qualification-program/transcript-biomarker-terminology-speaking-same-language [Last accessed on 16 Jan 2024].
7. Fridlyand J, Simon RM, Walrath JC, et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 2013;12:743-55.
8. Pickl M, Ruge E, Venturi M. Predictive markers in early research and companion diagnostic developments in oncology. N Biotechnol 2012;29:651-5.
9. Kafatos G, Banks V, Burdon P, et al. Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. Future Oncol 2021;17:1483-94.
10. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
11. Hélias-Rodzewicz Z, Funck-Brentano E, Baudoux L, et al. Variations of BRAF mutant allele percentage in melanomas. BMC Cancer 2015;15:497.
12. Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 2016;8:48-56.
13. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
14. Cheng YS, Williamson PR, Zheng W. Improving therapy of severe infections through drug repurposing of synergistic combinations. Curr Opin Pharmacol 2019;48:92-8.
15. Weth FR, Hoggarth GB, Weth AF, et al. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. Br J Cancer 2023.
16. Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 2020;54:34-44.
17. Mrozkowiak A, Olszewski WP, Piascik A, Olszewski WT. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Pol J Pathol 2004;55:165-71.
18. Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med 2017;15:55.
19. Corrado Rizzi. Failed CheckMate-026 lung cancer trial comes up in securities complaint against bristol-myers squibb. Avaliable from: https://www.classaction.org/news/failed-checkmate-026-lung-cancer-trial-comes-up-in-securities-complaint-against-bristol-myers-squibb [Last accessed on 16 Jan 2024].
20. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol 2016;22:4619-25.
21. Friedman CF, Hainsworth JD, Kurzrock R, et al. Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study. Cancer Discov 2022;12:654-69.
22. Administration USFaD. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Avaliable from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors [Last accessed on 16 Jan 2024].
23. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353-65.
24. Wittlinger F, Laufer SA. The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opin Drug Discov 2021;16:1091-103.
25. Butterworth S, Cross DAE, Finlay MRV, Ward RA, Waring MJ. The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M. Medchemcomm 2017;8:820-2.
27. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice; Lo B, Field MJ, editors. Conflict of Interest in Medical Research, Education, and Practice. Washington (DC): National Academies Press (US); 2009.
28. Vellanki PJ, Ghosh S, Pathak A, et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer 2023;11:e005344.
29. Administration USFaD. Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development; draft guidance for industry; availability. Avaliable from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-draft-guidance [Last accessed on 16 Jan 2024].
30. Hernandez KM, Bramlett KS, Agius P, et al. Contrived materials and a data set for the evaluation of liquid biopsy tests: a blood profiling atlas in cancer (BLOODPAC) community study. J Mol Diagn 2023;25:143-55.
31. Administration USFaD. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Avaliable from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication [Last accessed on 16 Jan 2024].
32. U.S. FDA approves FoundationOne®CDx as a companion diagnostic for KEYTRUDA® (pembrolizumab) to identify patients with microsatellite instability-high (MSI-H) solid tumors. Avaliable from: https://www.foundationmedicine.com/press-releases/u.s.-fda-approves-foundationone%C2%AEcdx-as-a-companion-diagnostic-for-keytruda%C2%AE-%28pembrolizumab%29-to-identify-patients-with-microsatellite-instability-high-%28msi-h%29-solid-tumors [Last accessed on 16 Jan 2024].
33. Marabelle A, Cesario J, Lang L, et al. 544 Companion diagnostic assays for pembrolizumab in patients with MSI-H/dMMR tumors. J Immunother Cancer 2022;10:A1-1063.
34. Administration USFaD. FDA approves larotrectinib for solid tumors with NTRK gene fusions. Avaliable from: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions [Last accessed on 16 Jan 2024].
35. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-9.
36. FoundationOne®CDx receives FDA-approval as a companion diagnostic for VITRAKVI®(larotrectinib) to identify patients with NTRK fusions across all solid tumors. Avaliable from: https://www.foundationmedicine.com/press-releases/foundationone%C2%AEcdx-receives-fda-approval-as-a-companion-diagnostic-for-vitrakvi%C2%AE(larotrectinib)-to-identify-patients-with-ntrk-fusions-across-all-solid-tumors#:~:text=today%20announced%20that%20it%20has,that%20have%20a%20neurotrophic%20receptor [Last accessed on 16 Jan 2024].
37. Cooper L, Chen J. Changes in companion diagnostic labelling: implementation of FDA’s April 2020 guidance for industry for in vitro CDx labeling for specific oncology therapeutic groups. Ther Innov Regul Sci 2022;56:689-97.
38. Moore MW, Babu D, Cotter PD. Challenges in the codevelopment of companion diagnostics. Per Med 2012;9:485-96.
39. Rockoff J. Tests are key but partners tricky. WSJ 2011;30. Avaliable from: https://www.wsj.com/articles/SB10001424053111903352704576538661653113814.html [Last accessed on 18 Jan 2024].
40. Jørgensen JT, Winther H. The development of the HercepTest™ - from bench to bedside. In: Jørgensen JT, Winther H, editors. Molecular diagnostics. New York: Jenny Stanford Publishing; 2010. p.18.
41. Emergen Research. Companion diagnostics market by technology (immunohistochemistry, in situ hybridization, polymerase chain reaction, genetic sequencing), by disease indication (breast cancer, lung cancer, colorectal cancer, skin cancer), by application (hospitals, diagnostic laboratories), by region, forecasts to 2017-2027. Avaliable from: https://www.emergenresearch.com/industry-report/companion-diagnostics-market [Last accessed on 16 Jan 2024].
42. Administration USFaD. Developing and labeling in vitro companion diagnostic devices for a specific group of oncology therapeutic products- guidance for industry. Avaliable from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-and-labeling-in-vitro-companion-diagnostic-devices-specific-group-oncology-therapeutic [Last accessed on 16 Jan 2024].
